AusTrials is pleased to have been involved in conducting the ARISE-HF Phase 3 trial which has since announced encouraging results. Applied Therapeutics, a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, has announced the topline results of the ARISE-HF Phase 3…
Indigenous peoples in high income countries are disproportionately affected by Type 2 Diabetes. Socioeconomic disadvantages and inadequate access to appropriate healthcare are important contributors. This systematic review, co-authored by Associate Professor Roy Rasalam (Principal Investigator at AusTrials Sunshine in Melbourne), investigates effective designs of primary care management of Type 2 Diabetes for Indigenous adults in…
Tirzepatide is a first-in-class GIP/GLP-1 receptor agonist (‘twincretin’)—a single molecule that acts as an agonist at both glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. In the SURPASS clinical trial program in type 2 diabetes mellitus (T2D), tirzepatide was associated with unprecedented reductions in HbA1c, clinically significant weight loss and other metabolic benefits,…
Early and intensive management of type 2 diabetes has been shown to delay disease progression, reduce the risk of cardiorenal complications and prolong time to treatment failure. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are being increasingly recognized for their potential in early disease management, with recent guideline updates recommending second-line use of this injectable drug class…
